Comparison of cellular metabolic responses of 18F-FDG according to the effect of β-irradiation in p53 wild and deleted cell lines

Cancer Biotherapy and Radiopharmaceuticals

Volumn 22, Issue 5, 2007, Pages 636-643

  Chung, Hye Kyung ^a   Cheon, Gi Jeong ^a   Choi, Chang Woon ^a   Kim, Min Jung ^a   Lee, Su Jae ^a   Lim, Sang Moo ^a  

^a Korea Institute of Radiation and Medical Science   (South Korea)

Author keywords

18F fluorodeoxyglucose (18F FDG); Beta irradiation; Cell cycle; Glucose metabolism; p 53

Indexed keywords

FLUORODEOXYGLUCOSE F 18; HEXOKINASE; PERRHENATE RE 188; PROTEIN P53; RHENIUM 188; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; CANCER RADIOTHERAPY; CELL ASSAY; CELL CYCLE; CELL CYCLE G2 PHASE; CELL LINE; CELL METABOLISM; CELL SURVIVAL; CELL VIABILITY; COLON ADENOCARCINOMA; COMPARATIVE STUDY; CONTROLLED STUDY; ELECTRON; ELECTRON THERAPY; ENERGY; ENZYME ACTIVITY; GLUCOSE METABOLISM; HUMAN; HUMAN CELL; MITOSIS INHIBITION; PRIORITY JOURNAL; TUMOR SUPPRESSOR GENE; WILD TYPE;

BETA RAYS; CELL CYCLE; CELL SURVIVAL; FLUORODEOXYGLUCOSE F18; GAMMA RAYS; GENE DELETION; HCT116 CELLS; HEXOKINASE; HUMANS; METABOLISM; RADIOISOTOPES; RHENIUM; TUMOR SUPPRESSOR PROTEIN P53;

EID: 35848960573     PISSN: 10849785     EISSN: None     Source Type: Journal    
DOI: 10.1089/cbr.2007.331     Document Type: Article

References (32)

1. Giaccia AJ, Kastan MB. The complexity of p53 modulation: Emerging patterns from divergent signals. Genes Dev 1998;12:2973.
2. Lowe SW, Ruley HE, Jacks T, et al. p53-dependent apoptosis modulates the cytotoxicity of anticancer agents. Cell 1993;74:957.
3. Velculescu VE, El-Deiry WS. Biological and clinical importance of the p53 tumor suppressor gene. Clin Chem 1996;42:858.
4. Zhao R, Gish K, Murphy M, et al. Analysis of p53-regulated gene expression patterns using oligonucleotide arrays. Genes Dev 2000;14:981.
5. Schwartz JL, Tamura Y, Jordan R, et al. Effect of p53 activation on cell growth, thymidine kinase-1 activity, and 3′-deoxy-3′ fluorothymidine uptake. Nucl Med Biol 2004;31:419.
6. Webster NJ, Resnik JL, Reichart DB, et al. Repression of the insulin receptor promoter by the tumor suppressor gene product p53: A possible mechanism for receptor overexpression in breast cancer. Cancer Res 1996;56:2781.
7. Schwartzenberg-Bar-Yoseph F, Armoni M, Karnieli E. The tumor suppressor p53 downregulates glucose transporters GLUT1 and GLUT4 gene expression. Cancer Res 2004;64:2627.
8. Xu RH, Pelicano H, Zhou Y, et al. Inhibition of glycolysis in cancer cells: A novel strategy to overcome drug resistance associated with mitochondrial respiratory defect and hypoxia. Cancer Res 2005;65:613.
9. Warburg O, Wind F, Negalein E. The metabolism of tumours in the body. J Physiol 1927;8:519.
10. Pauwels EKJ, Ribeiro MJ, Stoot JHMB, et al. FDG Accumulation and Tumor Biology. Nucl Med Biol 1998;25:317.
11. Orosz F, Wagner G, Ortega F, et al. Glucose conversion by multiple pathways in brain extract: Theoretical and experimental analysis. Biochem Biophys Res Commun 2003;309:792.
12. 188Re radiation in MCF7 cell line containing dominant negative mutant p53. Nucl Med Biol 2007;34:425.
13. 188Re solutions from alumina-based 188W-188Re generator. J Nucl Med 2000;41:1271.
14. Chen FD, Hsieh BT, Wang HE, et al. Efficacy of Re-188-labelled sulphur colloid on prolongation of survival time in melanoma-bearing animals. Nucl Med Biol 2001;28:835.
15. 2 arrest after DNA damage. Science 1998;282:1497.
16. Knapp FF, Callahan AP, Beets AL, et al. Processing of reactor-produced tungsten-188 for fabrication of clinical scale alumina-based tungsten-188/rhenium-188 generator. Appl Radiat Isot 1994;45:1123.
17. Hsieh BT, Liu CJ, Hsieh HS, et al. The preparation of W-188/Re-188 generator for therapeutic and diagnostic applications. Nucl Sci J 1996;23:26.
18. Mathupala SP, Heese C, Pedersen PL. Glucose catabolism in cancer cells. J Biol Chem 1997;272:22776.
19. Sheard MA, Uldrijan S, Vojtesek B. Role of p53 in regulating constitutive and X-radiation-inducible CD95 expression and function in carcinoma cells. Cancer Res 2003;63:7176.
20. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell 2000;100:57.
21. Levine AJ. p53, the cellular gatekeeper for growth and division. Cell 1997;88:323.
22. Nusser NN, Bartkowiak D, Röttinger EM. The influence of bromodeoxyuridine on the induction and repair of DNA double-strand breaks in glioblastoma cells. Strahlenther Onkol 2002;178:504.
23. Sviderskaya EV, Jazrawi E, Baldwin SA, et al. Cellular stress causes accumulation of the glucose transporter at the surface of cells independently of their insulin sensitivity. J Membr Biol 1996;149:133.
24. Kim J, Dang CV. Multifaceted roles of glycolytic enzymes. Trends Biochem Sci 2005;30:142.
25. Fujibayashi Y, Waki A, Sakahara H, et al. Transient increase in glycolytic metabolism in cultured tumor cells immediately after exposure to ionizing radiation: From gene expression to deoxyglucose uptake. Radiat Res 1997;147:729.
26. Gudkov AV, Komarova EA. The role of p53 in determining sensitivity to radiotherapy. Nat Rev Cancer 2003;3:117.
27. Wahl GM, Carr AM. The evolution of diverse biological responses to DNA damage: Insights from yeast and p53. Nat Cell Biol 2001;3:E277.
28. Prives C, Hall PA. The p53 pathway. J Pathol 1999;187:112.
29. Kolesnick R. The therapeutic potential of modulating the ceramide/sphingomyelin pathway. J Clin Invest 2002;110:3.
30. Rasey JS, Grierson JR, Wiens LW, et al. Validation of FLT uptake as a measure of thymidine kinase-1 activity in A549 carcinoma cells. J Nucl Med 2002;43:1210.
31. Agarwal ML, Agarwal A, Taylor WR, et al. p53 controls both the G2/M and the G1 cell-cycle checkpoints and mediates recersible growth arrest in human fibroblasts. Proc Natl Acad Sci USA 1995;92:8493.
32. Hyun JW, Cheon GJ, Kim HS, et al. Radiation sensitivity depends on OGG1 activity status in human leukemia cell lines. Free Rad Biol Med 2002;32:212.